Skip to main content
OpenTrials

Clinical trial condition

Hematological Malignancies

Explore clinical trials studying Hematological Malignancies. Study availability and eligibility vary by location and protocol.

98 public trials 21 recruiting studies
Refine in advanced search Browse all conditions

Hematological Malignancies trial results

Completed

A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004)

NCT05005442

Conditions
Hematologic Diseases, Hematologic Neoplasms, Hematological Malignancies, +3 more
Locations
  • City of Hope Comprehensive Cancer Center-Hematology ( Site 0024) Duarte, California, United States
  • University of Colorado Anschutz Medical Campus-The Center for Cancer and Blood Disorders ( Site 0021 Aurora, Colorado, United States
  • University of Chicago Medical Center ( Site 0005) Chicago, Illinois, United States
  • Henry Ford Hospital ( Site 0003) Detroit, Michigan, United States
View all 65 locations
View Trial Details
Completed

Establish the PK of Belinostat in Patients With Wild-type, Heterozygous, and Homozygous UGT1A1*28 Genotypes

NCT02680795

Conditions
Hematologic Diseases, Hematologic Neoplasms, Hematological Malignancies, +4 more
Locations
  • John Wayne Cancer Institute @ Providence Saint John's Health Center Santa Monica, California, United States
  • The Oncology Institute of Hope and Innovation Whittier, California, United States
  • Gabrail Cancer Center Research Canton, Ohio, United States
View Trial Details
Completed

Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects

NCT04283097

Conditions
Hematologic Diseases, Hematologic Neoplasms, Hematological Malignancies, +3 more
Locations
  • UC Davis Comprehensive Cancer Center Sacramento, California, United States
  • BRCR Global - USA Plantation, Florida, United States
  • Norton Cancer Institute Louisville, Kentucky, United States
  • Henry Ford Health System - Hemophilia and Thrombosis Treatment Center Detroit, Michigan, United States
View Trial Details
Completed

Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers

NCT00788684

Conditions
CD20-Positive Lymphoid Malignancies, Chronic Lymphoid Leukemia, Hematologic Diseases, +16 more
Locations
  • University of Arizona Cancer Center - North Campus /ID# 16721 Tucson, Arizona, United States
  • Stanford University School of Med /ID# 9782 Stanford, California, United States
  • Cleveland Clinic Main Campus /ID# 9784 Cleveland, Ohio, United States
  • Univ of Wisconsin Hosp/Clinics /ID# 21701 Madison, Wisconsin, United States
View Trial Details
Completed

Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies

NCT02576496

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Cutaneous T Cell Lymphoma, +23 more
Locations
  • Mayo Clinic Phoenix, Arizona, United States
  • Mayo Clinic Cancer Center Jacksonville, Florida, United States
  • Columbia University Medical Center New York, United States
  • University Hospitals Cleveland Seidman Cancer Center Cleveland, Ohio, United States
View all 18 locations
View Trial Details

Related conditions